156 related articles for article (PubMed ID: 11780146)
1. Structure of the Bcr-Abl oncoprotein oligomerization domain.
Zhao X; Ghaffari S; Lodish H; Malashkevich VN; Kim PS
Nat Struct Biol; 2002 Feb; 9(2):117-20. PubMed ID: 11780146
[TBL] [Abstract][Full Text] [Related]
2. Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide.
Huang SF; Liu DB; Zeng JM; Xiao Q; Luo M; Zhang WP; Tao K; Wen JP; Huang ZG; Feng WL
Protein Expr Purif; 2009 Apr; 64(2):167-78. PubMed ID: 19041400
[TBL] [Abstract][Full Text] [Related]
3. Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain.
Taylor CM; Keating AE
Biochemistry; 2005 Dec; 44(49):16246-56. PubMed ID: 16331985
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl.
Hantschel O; Wiesner S; Güttler T; Mackereth CD; Rix LL; Mikes Z; Dehne J; Görlich D; Sattler M; Superti-Furga G
Mol Cell; 2005 Aug; 19(4):461-73. PubMed ID: 16109371
[TBL] [Abstract][Full Text] [Related]
6. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
[TBL] [Abstract][Full Text] [Related]
7. Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.
Martinelli G; Amabile M; Giannini B; Terragna C; Ottaviani E; Soverini S; Saglio G; Rosti G; Baccarani M
Haematologica; 2002 Jul; 87(7):688-94; discussion 694. PubMed ID: 12091118
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Shah NP; Sawyers CL
Oncogene; 2003 Oct; 22(47):7389-95. PubMed ID: 14576846
[TBL] [Abstract][Full Text] [Related]
9. Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein.
San Juan AA
J Mol Graph Model; 2007 Sep; 26(2):482-93. PubMed ID: 17446106
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.
Skaggs BJ; Gorre ME; Ryvkin A; Burgess MR; Xie Y; Han Y; Komisopoulou E; Brown LM; Loo JA; Landaw EM; Sawyers CL; Graeber TG
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19466-71. PubMed ID: 17164333
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
12. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
13. Solution structure of the symmetric coiled coil tetramer formed by the oligomerization domain of hnRNP C: implications for biological function.
Whitson SR; LeStourgeon WM; Krezel AM
J Mol Biol; 2005 Jul; 350(2):319-37. PubMed ID: 15936032
[TBL] [Abstract][Full Text] [Related]
14. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.
Yamamoto M; Kurosu T; Kakihana K; Mizuchi D; Miura O
Biochem Biophys Res Commun; 2004 Jul; 319(4):1272-5. PubMed ID: 15194504
[TBL] [Abstract][Full Text] [Related]
15. SRCircumventing imatinib resistance.
Deininger MW; Druker BJ
Cancer Cell; 2004 Aug; 6(2):108-10. PubMed ID: 15324693
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells.
Mishra S; Reichert A; Cunnick J; Senadheera D; Hemmeryckx B; Heisterkamp N; Groffen J
Oncogene; 2003 Nov; 22(51):8255-62. PubMed ID: 14614449
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of Bcr-abl... breaking new ground again.
Ohren JF; Sebolt-Leopold JS
Nat Chem Biol; 2006 Feb; 2(2):63-4. PubMed ID: 16421581
[No Abstract] [Full Text] [Related]
19. The hyperthermophile protein Sso10a is a dimer of winged helix DNA-binding domains linked by an antiparallel coiled coil rod.
Chen L; Chen LR; Zhou XE; Wang Y; Kahsai MA; Clark AT; Edmondson SP; Liu ZJ; Rose JP; Wang BC; Meehan EJ; Shriver JW
J Mol Biol; 2004 Jul; 341(1):73-91. PubMed ID: 15312764
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
